These combinations are common in my Anela Protocols. Of the 25 protocols I've written, GHK-CU was one of my first and is probably my most recognized protocol.

During my visit to Janoshik Analytical in Prague, I had the opportunity to sit down with Peter Magic and ask him about this claim. Paid subscribers get to see the video and Janoshik's answer first.

Rather than rely on what people are repeating on social media, I wanted to hear what the analytical testing actually shows. Peter, at Janoshik has a pretty logical answer. This is just one small excerpt from our half hour interview while I was visiting his lab. And by the way, Prague is a beautiful city!

The one exception was GHKCU. When injection site reactions came up around GHKCU, my first thought was usually BPC. But sometimes BPC wasn't a fit, whether from angiogenesis concerns, oncology related concerns, or just not getting the response people wanted, or research complications such as anhedonia. That's when I'd point people toward KPV instead.

What first caught my attention about KPV was its mast cell stabilizing activity. I never thought it was as strong as BPC in that role, but it earned a place in a handful of protocols I looked at, and over time I found myself bringing it up for GI related discussions too. That was about it. I didn't think of it for pain and inflammation. I never imagined it would come up in a conversation about comfort or quality of life research.

At least that's what I thought back then.

One research project changed everything.

Earlier this year (January, 2026), I went back through a stack of KPV citations for a project that pushed me to look much harder at compounds outside my usual short list. *The goal of that project was comfort and quality of life above everything else, and major angiogenesis concerns took several of the usual go to compounds off the table*.

When your options get that small, you start looking a lot closer at the ones you'd normally skip past.

That's when I really dug into KPV, and I was blown away by what was already sitting in the literature. That was the point where I stopped treating KPV as just a GI peptide and started looking at it completely differently.

KPV wasn't discovered as a standalone peptide. It started out as the three amino acid tail end of alpha MSH, a naturally occurring peptide made by the body. Researchers found this tiny fragment kept much of the anti inflammatory activity of the larger peptide. It's just three amino acids. Lysine, proline, valine. For something so small, there is an impressive amount of published work behind it.

Most people know KPV from GI research, and that's fair. Some of the strongest work has been done in inflammatory bowel disease research, intestinal inflammation, barrier function, and mucosal healing research. I thought that's where the story ended. It doesn't.

The more papers/research I went through, the more KPV kept showing up in places I wasn't expecting. Skin. Wound healing. Immune regulation. Macrophage activity. Barrier function. Inflammation. The list of research applications kept growing.

The skin research really caught my attention. KPV has been studied in inflammatory skin conditions and skin barrier health, which opens the door to something I think deserves a lot more attention, *topical and intranasal formulations*. At around 417 Daltons (Da), KPV is small enough that more than one route of administration/research comes up in discussion.

For a research peptide to be used intranasally or topically, it needs to be at or under 1,000 Da, KPV fits that.

For topical formulations, raw KPV powder is the way to go, lyophilized KPV isn't right for that. A 3% cream using a CeraVe type base has become my preferred reference point when this comes up. Its small size also makes intranasal delivery an interesting topic, which wasn't even on my radar a few years ago. Now it is.

I've also noticed that some discussions around BPC and TB alone tend to shift once KPV gets added to the conversation. I've seen that pattern often enough that I pay attention to it now. That changed how I think about protocol design in general. Years ago my thinking was BPC or KPV. Today it's whether KPV belongs in the conversation too, not because it replaces either one, but because it brings something different.

I also appreciate what KPV isn't. Based on the literature available today, it isn't known to cross the blood brain barrier, and it isn't known to promote angiogenesis. That doesn't prove it never could, it just means that concern hasn't shown up the way it has with some other compounds. For anyone thinking through oncology related concerns, that's worth knowing.

I don't like getting into dosing specifics in public forums, but I'll say this much. The general dosing range people discuss for KPV lines up closely with BPC, and a loading phase comes up often in that same conversation. That's a sentence I never thought I'd write.

If you had asked me a few years ago whether KPV deserved a permanent place on my radar, I probably would have laughed. Not because I disliked it, I just didn't think it brought enough to the table.

I was wrong.

I still don't think KPV replaces BPC. I still don't think it belongs in every protocol. What I do think is that it deserves far more respect than it gets. It's easy to overlook because it's only three amino acids, easy to overlook because it doesn't get talked about like the bigger names, and easy to overlook because a lot of us put it in a small box years ago and never looked again.

This year forced me to look again. I'm glad it did. It reminded me that no matter how long you've been in this space, you should never stop questioning your own assumptions.

If January, 2026 had never happened, I'd probably still be telling people that KPV and BPC were like drinking Coke and Pepsi at the same time. I don't believe that anymore.

KPV earned my respect the hard way, my research subject benefited exponentially and I will always be grateful for that. 🥹

Disclaimer: 𝑇ℎ𝑖𝑠 𝑝𝑜𝑠𝑡 𝑟𝑒𝑓𝑙𝑒𝑐𝑡𝑠 𝑝𝑒𝑟𝑠𝑜𝑛𝑎𝑙 𝑜𝑝𝑖𝑛𝑖𝑜𝑛 𝑎𝑛𝑑 𝑎 𝑟𝑒𝑣𝑖𝑒𝑤 𝑜𝑓 𝑝𝑢𝑏𝑙𝑖𝑠ℎ𝑒𝑑 𝑙𝑖𝑡𝑒𝑟𝑎𝑡𝑢𝑟𝑒. 𝐼𝑡 𝑖𝑠 𝑖𝑛𝑡𝑒𝑛𝑑𝑒𝑑 𝑓𝑜𝑟 𝑟𝑒𝑠𝑒𝑎𝑟𝑐ℎ 𝑎𝑛𝑑 𝑖𝑛𝑓𝑜𝑟𝑚𝑎𝑡𝑖𝑜𝑛𝑎𝑙 𝑝𝑢𝑟𝑝𝑜𝑠𝑒𝑠 𝑜𝑛𝑙𝑦. 𝑁𝑜𝑡ℎ𝑖𝑛𝑔 ℎ𝑒𝑟𝑒 𝑖𝑠 𝑚𝑒𝑑𝑖𝑐𝑎𝑙 𝑎𝑑𝑣𝑖𝑐𝑒, 𝑎𝑛𝑑 𝑛𝑜𝑡ℎ𝑖𝑛𝑔 ℎ𝑒𝑟𝑒 𝑟𝑒𝑓𝑒𝑟𝑠 𝑡𝑜 ℎ𝑢𝑚𝑎𝑛 𝑢𝑠𝑒. 𝑃𝑒𝑝𝑡𝑖𝑑𝑒𝑠 𝑑𝑖𝑠𝑐𝑢𝑠𝑠𝑒𝑑 𝑎𝑟𝑒 𝑛𝑜𝑡 𝑎𝑝𝑝𝑟𝑜𝑣𝑒𝑑 𝑓𝑜𝑟 ℎ𝑢𝑚𝑎𝑛 𝑐𝑜𝑛𝑠𝑢𝑚𝑝𝑡𝑖𝑜𝑛 𝑜𝑟 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝑜𝑓 𝑎𝑛𝑦 𝑐𝑜𝑛𝑑𝑖𝑡𝑖𝑜𝑛. 𝑁𝑜𝑡 𝑎 𝑑𝑜𝑐𝑡𝑜𝑟, 𝑛𝑜𝑡 𝑚𝑒𝑑𝑖𝑐𝑎𝑙 𝑎𝑑𝑣𝑖𝑐𝑒.

~ Anela